MedTrace Logo

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05177770 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-05-08

Study results available
· View outcomes & findings →

Summary

This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Interventions

DRUG

SRF617

SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.

DRUG

etrumadenant

Etrumadenant is an A2aR and A2bR antagonist.

DRUG

zimberelimab

Zimberelimab is a fully human anti-PD-1 monoclonal antibody.

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    collaborator INDUSTRY

  • Surface Oncology

    collaborator INDUSTRY

  • Coherus Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Vienna Reichert, PhD · Coherus BioSciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2023-04-05
Completion
2023-04-05
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177770 on ClinicalTrials.gov